Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Okumura S, Konishi Y, Narukawa M, Sugiura Y, Yoshimoto S, Arai Y, Sato S, Yoshida Y, Tsuji S, Uemura K, Wakita M, Matsudaira T, Matsumoto T, Kawamoto S, Takahashi A, Itatani Y, Miki H, Takamatsu M, Obama K, Takeuchi K, Suematsu M, Ohtani N, Fukunaga Y, Ueno M, Sakai Y, Nagayama S, Hara E
Journal
Nature communications
Year
2021
Emerging evidence is revealing that alterations in gut microbiota are associated with colorectal cancer (CRC). However, very little is currently known about whether and how gut microbiota alterations are causally associated with CRC development. Here we show that 12 faecal bacterial taxa are enriched in CRC patients in two independent cohort studies. Among them, 2 Porphyromonas species are capable of inducing cellular senescence, an oncogenic stress response, through the secretion of the bacterial metabolite, butyrate. Notably, the invasion of these bacteria is observed in the CRC tissues, coinciding with the elevation of butyrate levels and signs of senescence-associated inflammatory phenotypes. Moreover, although the administration of these bacteria into ApcΔ14/+ mice accelerate the onset of colorectal tumours, this is not the case when bacterial butyrate-synthesis genes are disrupted. These results suggest a causal relationship between Porphyromonas species overgrowth and colorectal tumourigenesis which may be due to butyrate-induced senescence.
Experiment 1
Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10
Subjects
- Location of subjects
- Japan
- Host species Species from which microbiome was sampled (if applicable)
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy Individuals
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Patients with CRC
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- patients with CRC verified disease state via colonoscopy
- Group 0 sample size Number of subjects in the control (unexposed) group
- 384
- Group 1 sample size Number of subjects in the case (exposed) group
- 380
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 1 Month
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V1-V2
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Signature 1
Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10
Source: Figure 1A
Description: Differential microbial abundance between CRC patients and healthy controls
Abundance in Group 1: increased abundance in Patients with CRC
Revision editor(s): Jeshudy, Claregrieve1
Experiment 2
Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Patients with early CRC
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with early colorectal cancer
- Group 0 sample size Number of subjects in the control (unexposed) group
- 129
- Group 1 sample size Number of subjects in the case (exposed) group
- 136
Signature 1
Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10
Source: Figure 1B
Description: Differential microbial abundance between early CRC patients and healthy controls
Abundance in Group 1: increased abundance in Patients with early CRC
| NCBI | Quality Control | Links |
|---|---|---|
| Fusobacterium nucleatum | ||
| Gemella morbillorum | ||
| Peptostreptococcus stomatis |
Revision editor(s): Jeshudy, Claregrieve1
Experiment 3
Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Patients with advanced CRC
- Group 1 sample size Number of subjects in the case (exposed) group
- 153
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10
Source: Figure 1B
Description: Differential microbial abundance between advanced CRC patients and healthy controls
Abundance in Group 1: increased abundance in Patients with advanced CRC
Revision editor(s): Jeshudy, Claregrieve1
Experiment 4
Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Before resection
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- After resection
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients post surgical resection of Cohort-1 CRC specimens
- Group 0 sample size Number of subjects in the control (unexposed) group
- 380
- Group 1 sample size Number of subjects in the case (exposed) group
- 380
Signature 1
Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10
Source: Figure 1C
Description: Differential microbial abundance in samples before and after surgical resection of primary tumors.
Abundance in Group 1: decreased abundance in After resection
Revision editor(s): Jeshudy, Claregrieve1
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_624&oldid=105487"
Hidden category:
